ROCHE HOLDINGS AG (RHHBY)

33.83
0.07 0.21
OTC
Prev Close 33.76
Open 33.87
Day Low/High 33.74 / 33.93
52 Wk Low/High 26.30 / 34.98
Volume 399.60K
Exchange OTC
Shares Outstanding 702.56B
Market Cap 195.59B
Div & Yield N.A. (N.A)
Genentech Announces FDA Grants Venclexta Accelerated Approval For People With Newly-Diagnosed Acute Myeloid Leukemia Or Those Who Are Ineligible For Intensive Induction Chemotherapy

Genentech Announces FDA Grants Venclexta Accelerated Approval For People With Newly-Diagnosed Acute Myeloid Leukemia Or Those Who Are Ineligible For Intensive Induction Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Genentech To Present New Data From Its Industry-Leading Hematology Portfolio At The American Society Of Hematology (ASH) 2018 Annual Meeting

Genentech To Present New Data From Its Industry-Leading Hematology Portfolio At The American Society Of Hematology (ASH) 2018 Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60...

Roche Diagnostics To Replace CoaguChek® XS PT Test Strips

Roche Diagnostics To Replace CoaguChek® XS PT Test Strips

INDIANAPOLIS, Oct. 31, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY): This notification supplements previous Urgent Medical Device Correction (UMDC) communications initially issued by Roche Diagnostics on September 12, 2018 and updated on...

Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities

Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta ® (venetoclax) in combination with Gazyva ® (obinutuzumab) in people with previously...

New Stairway Study Data Shows Potential For Extended Durability With Faricimab In Wet Age-Related Macular Degeneration (AMD)

New Stairway Study Data Shows Potential For Extended Durability With Faricimab In Wet Age-Related Macular Degeneration (AMD)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration...

Genentech Announces FDA Approval Of XOFLUZA (Baloxavir Marboxil) For Influenza

Genentech Announces FDA Approval Of XOFLUZA (Baloxavir Marboxil) For Influenza

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech's Investigational Personalized Medicine Entrectinib Shrank Tumors In People With NTRK Fusion-Positive Solid Tumors

Genentech's Investigational Personalized Medicine Entrectinib Shrank Tumors In People With NTRK Fusion-Positive Solid Tumors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials that showed the investigational personalized...

Genentech's Tecentriq In Combination With Abraxane Improves Outcomes As An Initial Treatment For People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Genentech's Tecentriq In Combination With Abraxane Improves Outcomes As An Initial Treatment For People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane ® [albumin-bound paclitaxel; nab-paclitaxel]) for the...

FDA Approves Label Update For Genentech's Rituxan (Rituximab) In Two Rare Forms Of Vasculitis

FDA Approves Label Update For Genentech's Rituxan (Rituximab) In Two Rare Forms Of Vasculitis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

SQZ Biotech Expands Cell Therapy Partnership With Roche To Develop Antigen Presenting Cells For Immune-Oncology

SQZ Biotech Expands Cell Therapy Partnership With Roche To Develop Antigen Presenting Cells For Immune-Oncology

- Collaboration combines SQZ Biotech's novel cell therapy platform with Roche's cancer immunotherapy expertise

Genentech's Kadcyla Reduced The Risk Of Disease Recurring In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech's Kadcyla Reduced The Risk Of Disease Recurring In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease...

OCREVUS (Ocrelizumab) Data Show Early Initiation Of Treatment Reduces Disability Progression Over Five Years In Relapsing And Primary Progressive Multiple Sclerosis

OCREVUS (Ocrelizumab) Data Show Early Initiation Of Treatment Reduces Disability Progression Over Five Years In Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from...

Genentech To Present New Positive Data From Its Broad Cancer Immunotherapy Program And Across A Wide Range Of Cancers At The European Society For Medical Oncology (ESMO) 2018 Congress

Genentech To Present New Positive Data From Its Broad Cancer Immunotherapy Program And Across A Wide Range Of Cancers At The European Society For Medical Oncology (ESMO) 2018 Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new results from a number of studies across its industry-leading oncology portfolio of approved and investigational medicines will be presented at the European...

FDA Approves Genentech's Hemlibra (Emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors

FDA Approves Genentech's Hemlibra (Emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Positive Phase III Results For Baloxavir Marboxil In People At High Risk Of Complications From Influenza To Be Presented At IDWeek 2018

Positive Phase III Results For Baloxavir Marboxil In People At High Risk Of Complications From Influenza To Be Presented At IDWeek 2018

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo (median...

Genentech Announces New Data For Risdiplam In Spinal Muscular Atrophy (SMA) At The World Muscle Society Congress

Genentech Announces New Data For Risdiplam In Spinal Muscular Atrophy (SMA) At The World Muscle Society Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam (RG7916) in spinal muscular atrophy (SMA).

Genentech To Present Five-Year OCREVUS (Ocrelizumab) Efficacy And Safety Data In Relapsing And Primary Progressive Multiple Sclerosis At ECTRIMS

Genentech To Present Five-Year OCREVUS (Ocrelizumab) Efficacy And Safety Data In Relapsing And Primary Progressive Multiple Sclerosis At ECTRIMS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of MS will be presented during the 34th Congress of the European Committee...

FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation

FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People Live Significantly Longer As An Initial Treatment For People With Extensive-Stage Small Cell Lung Cancer

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People Live Significantly Longer As An Initial Treatment For People With Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower133 study of TECENTRIQ ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of...

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In A Type Of Previously Untreated Advanced Lung Cancer

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In A Type Of Previously Untreated Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III IMpower132 study of TECENTRIQ ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial...

Genentech's Investigational Medicine Entrectinib Showed A Durable Response Of More Than Two Years In People With A Specific Type Of Lung Cancer

Genentech's Investigational Medicine Entrectinib Showed A Durable Response Of More Than Two Years In People With A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials, which...

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis (SJIA), A Rare Form Of Juvenile Arthritis

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis (SJIA), A Rare Form Of Juvenile Arthritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech To Present New Data From Its Extensive Lung Cancer Program At The 2018 World Conference On Lung Cancer (WCLC)

Genentech To Present New Data From Its Extensive Lung Cancer Program At The 2018 World Conference On Lung Cancer (WCLC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from its broad clinical development program across different types of lung cancer will be presented at the International Association for the Study of Lung...

3 Biotech Stocks Ready to Burn Up

3 Biotech Stocks Ready to Burn Up

Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.

Positive Phase III Results For Genentech's HEMLIBRA (emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors Published In New England Journal Of Medicine

Positive Phase III Results For Genentech's HEMLIBRA (emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA ® (emicizumab-kxwh) prophylaxis administered every week or every two weeks in adults and...

FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies

FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.